Advertisement

Topics

Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B

16:37 EDT 28 Jul 2017 | FinanzNachrichten

BERKELEY, CA--(Marketwired - July 28, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Pro...

Original Article: Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B

NEXT ARTICLE

More From BioPortfolio on "Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...